BofA/Merrill Lynch Downgrades Nektar Therapeutics (NKTR) to Underperform
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $73.02 -3.82%
Rating Summary:
20 Buy, 7 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
20 Buy, 7 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Nektar Therapeutics (NASDAQ: NKTR) from Neutral to Underperform.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $6.30 yesterday.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $6.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
- Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
